

- B1
- (a) encodes the amino acid sequence shown in SEQ ID NO:7; and
 - (b) hybridizes to the nucleotide sequence of SEQ ID NO:6 or the complement thereof under highly stringent conditions of 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS) and 1 mM EDTA at 65°C and washing in 0.1x SSC/0.1%SDS at 68°C.
-

Please add new claims 9-11 as follows:

--9. (New) The isolated nucleic acid molecule of claim 4, comprising the nucleic acid sequence of SEQ ID NO:6.

B2 10. (New) The recombinant expression vector of claim 7, wherein said nucleic acid molecule encodes the amino acid sequence shown in SEQ ID NO:7.

11. (New) The recombinant expression vector of claim 10, wherein said nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO:6.--

RESPONSE

I. Status of the Claims

No claims have been cancelled. Claim 5 has been amended. New claims 9-11 have been added.

Claims 4-11 are therefore presently pending in the case. For the convenience of the Examiner, a clean copy of the pending claims is attached hereto as **Exhibit A**. In compliance with 37 C.F.R. § 1.121(c)(1)(ii), a marked up copy of the original claims is attached hereto as **Exhibit B**.

II. Support for the Amended and Newly Added Claims

Claim 5 has been amended to recite specific highly stringent hybridization conditions. Support for these claims can be found throughout the specification as originally filed, with particular support being found at least at page 8, lines 5-14.

Claim 9 has been added to specifically recite an isolated nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO:6. Support for this claim can be found throughout the

specification as originally filed, with specific support being found at least in Section 5.1.

Claim 10 has been added to specifically recite a recombinant expression vector comprising a nucleic acid molecule that encodes SEQ ID NO:7. Support for this claim can be found throughout the specification as originally filed, with specific support being found at least in original claim 6 and at page 13, lines 21-26.

Claims 11 has been added to specifically recite a recombinant expression vector comprising an isolated nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO:6. Support for this claim can be found throughout the specification as originally filed, with particular support being found at least in Section 5.1 and at page 13, lines 21-26.

It will be understood that no new matter is included within the amended or newly added claims.

III. Rejection of Claims 4-8 Under 35 U.S.C. § 101

The Action first rejects claims 4-8 under 35 U.S.C. § 101, as allegedly lacking a patentable utility. Applicants respectfully traverse.

The present invention has a number of substantial and credible utilities, not the least of which is in diagnostic assays, as described in the specification, at least at page 10, line 35. As described in the specification from page 7, line 37 through page 8, line 2, the present sequence defines a coding single nucleotide polymorphism - specifically, an A/T polymorphism at position 598 of SEQ ID NO:6, which can lead to an isoleucine or valine residue at amino acid position 200 of SEQ ID NO:7. As such polymorphisms are the basis for diagnostic assays such as forensic analysis, which is undoubtedly a “real world” utility, the present sequences must in themselves be useful. It is important to note that the presence of more useful polymorphic markers for forensic analysis would not mean that the present sequences lack utility. As clearly set forth by the Federal Circuit in *Carl Zeiss Stiftung v. Renishaw PLC*, 20 USPQ2d 1101 (Fed. Cir. 1991):

An invention need not be the best or only way to accomplish a certain result, and it need only be useful to some extent and in certain applications: “[T]he fact that an invention has only limited utility and is only operable in certain applications is not grounds for finding a lack of utility.” *Envirotech Corp. v. Al George, Inc.*, 221 USPQ 473, 480 (Fed. Cir. 1984)

Just because other polymorphic sequences from the human genome have been described does not mean that the use of the presently described polymorphic marker for forensic analysis is not a specific utility.

Additionally, Applicants would like to invite the Examiner’s attention to the fact that four

sequences sharing 100% percent identity at the protein level over an extended region of the claimed sequence are present in the leading scientific repository for biological sequence data (GenBank), and have been annotated by third party scientists who are *wholly unaffiliated with Applicants* as “Homo sapiens platelet derived growth factor C” (Li *et al.*, Nat. Cell Biol. 2:302-309, 2000 and Gilbertson *et al.*, J. Biol. Chem. 276:27406-27414, 2001; GenBank accession numbers NM_016205 and AF260738; abstracts, alignments and GenBank reports shown in **Exhibit C**), “Homo sapiens secretory growth factor-like protein fallotein” (which is a member of the PDGF family; Tsai *et al.*, Biochim. Biophys. Acta 1492:196-202, 2000; abstract, alignment and GenBank report shown in **Exhibit D**), and “Homo sapiens hSCDGF mRNA for spinal-cord-derived growth factor (which is also a member of the PDGF family; Hamada *et al.*, FEBS Lett. 475:97-102, 2000; abstract, alignment and GenBank report shown in **Exhibit E**). The legal test for utility simply involves an assessment of whether those skilled in the art would find any of the utilities described for the invention to be credible or believable. Given these GenBank annotations, there can be no question that those skilled in the art would clearly believe that Applicants’ sequence is a platelet derived growth factor, as described in the specification as originally filed, at least from page 2, line 34 to page 3, line 1. Given the well established biological and medical relevance of platelet derived growth factor proteins, those of skill in the art would readily appreciate the utility of the present sequence in numerous applications, as described herein and in the specification as originally filed. Thus, the present claims clearly meet the requirements of 35 U.S.C. § 101.

The Action cites an article by Skolnick *et al.* (“Skolnick”; 2000, Trends in Biotech. 18:34-39) for the proposition that “(k)nowing the protein structure by itself is insufficient to annotate a number of functional classes and is also insufficient for annotating the specific details of protein function” (Skolnick at page 36, emphasis added). However, Skolnick concerns predicting protein function not by overall amino acid homology to other family members, but instead concerns prediction of function based on the presence of certain functional “motifs” present within a given protein sequence. Thus, Skolnick does not apply to the current situation, where overall protein homology is used to assign function to a particular sequence. However, even in the event that Skolnick is applicable, Skolnick itself concludes that “sequence-based approaches to protein-function prediction have proved to be very useful” (Skolnick at page 37), admitting that such methods have correctly assigned function in 50-70% of the cases, thus arguing against the conclusion drawn in the Action.

The Action next cites an issued U.S. Patent to Tischer *et al.* (U.S. Patent No. 5,194,596;

“Tischer”) for the proposition that individual members of a protein family can “have distinct, and sometimes even opposite, biological activities” (Action at page 4). While this may in fact be the case, an unusual case such as this, particularly one disclosed in a patent based on an application filed in 1989, ten years before the filing of the present application, hardly represents the view of those skilled in the art at the time of the present application regarding prediction of protein function based on homology. Applicants submit that, as described above, those skilled in the art in 1999 would clearly believe that Applicants’ sequence is a platelet derived growth factor.

The Action finally cites Yan *et al.* (2000, Science 290:523-527; “Yan”) to question asserted utility based upon protein homology. However, Yan cites only one example, two isoforms of the anhidrotic ectodermal dysplasia (EDA) gene, where a two amino acid change conforms one isoform (EDA-A1) into the second isoform (EDA-A2). However, while it is true that this amino acid change results in binding to different receptors, it is important to note that the different receptors bound by the two isoforms are in fact related (Yan at page 523). Furthermore, the EDA-A2 receptor was correctly identified as a member of the tumor necrosis factor receptor superfamily based solely on sequence similarity (Yan at page 523). Thus, Yan does not suggest a high level of uncertainty in assigning function based on sequence, and thus also does not support the alleged lack of utility.

Although Applicants need only make one credible assertion of utility to meet the requirements of 35 U.S.C. § 101 (*Raytheon v. Roper*, 220 USPQ 592 (Fed. Cir. 1983); *In re Gottlieb*, 140 USPQ 665 (CCPA 1964); *In re Malachowski*, 189 USPQ 432 (CCPA 1976); *Hoffman v. Klaus*, 9 USPQ2d 1657 (Bd. Pat. App. & Inter. 1988)), as a further example of the utility of the presently claimed polynucleotide, as described in the specification at least at page 10, lines 34-35, the present nucleotide sequences have a specific utility in “determining the genomic structure”, for example in the identification of coding sequence and mapping the gene to a particular chromosome. This is evidenced by the fact that SEQ ID NO:6 can be used to map the 5 coding exons on chromosome 4 (present within two overlapping chromosome 4 clones; Genbank Accession Numbers AC093325 and AC092608; alignments and the first page from the Genbank reports are presented in **Exhibit F**). Clearly, the present polynucleotide provides exquisite specificity in localizing the specific region of human chromosome 4 that contains the gene encoding the given polynucleotide, a utility not shared by virtually any other nucleic acid sequences. In fact, it is this specificity that makes this particular sequence so useful. Early gene mapping techniques relied on methods such as Giemsa staining to identify regions of chromosomes. However, such techniques produced genetic maps with a resolution

of only 5 to 10 megabases, far too low to be of much help in identifying specific genes involved in disease. The skilled artisan readily appreciates the significant benefit afforded by markers that map a specific locus of the human genome, such as the present nucleic acid sequence.

Applicants respectfully remind the Examiner that only a minor percentage (2-4%) of the genome actually encodes exons, which in-turn encode amino acid sequences. The presently claimed polynucleotide sequence provides biologically validated empirical data (*e.g.*, showing which sequences are transcribed, spliced, and polyadenylated) that *specifically* define that portion of the corresponding genomic locus that actually encodes exon sequence, as described above. Equally significant is that the claimed polynucleotide sequence defines how the encoded exons are actually spliced together to produce an active transcript (*i.e.*, the described sequences are useful for functionally defining exon splice-junctions). The specification details that “sequences derived from regions adjacent to the intron/exon boundaries of the human gene can be used to design primers for use in amplification assays to detect mutations within the exons, introns, splice sites (*e.g.*, splice acceptor and/or donor sites), *etc.*, that can be used in diagnostics and pharmacogenomics” (specification from page 10, line 36 to page 11, line 3). Applicants respectfully submit that the practical scientific value of biologically validated, expressed, spliced, and polyadenylated mRNA sequences is readily apparent to those skilled in the relevant biological and biochemical arts. For further evidence in support of the Applicants’ position, the Examiner is requested to review, for example, section 3 of Venter *et al.* (2001, *Science* 291:1304 at pp. 1317-1321, including Fig. 11 at pp.1324-1325), which demonstrates the significance of expressed sequence information in the structural analysis of genomic data. The presently claimed polynucleotide sequence defines a biologically validated sequence that provides a unique and specific resource for mapping the genome essentially as described in the Venter *et al.* article. Thus, the present claims clearly meet the requirements of 35 U.S.C. § 101.

Rather, as set forth by the Federal Circuit, “(t)he threshold of utility is not high: An invention is ‘useful’ under section 101 if it is capable of providing some identifiable benefit.” *Juicy Whip Inc. v. Orange Bang Inc.*, 51 USPQ2d 1700 (Fed. Cir. 1999) (citing *Brenner v. Manson*, 383 U.S. 519, 534 (1966)). Additionally, the Federal Circuit has stated that “(t)o violate § 101 the claimed device must be totally incapable of achieving a useful result.” *Brooktree Corp. v. Advanced Micro Devices, Inc.*, 977 F.2d 1555, 1571 (Fed. Cir. 1992), emphasis added. *Cross v. Iizuka* (224 USPQ 739 (Fed. Cir. 1985); “*Cross*”) states “any utility of the claimed compounds is sufficient to satisfy 35 U.S.C. § 101”. *Cross* at 748, emphasis added. Indeed, the Federal Circuit recently emphatically

confirmed that "anything under the sun that is made by man" is patentable (*State Street Bank & Trust Co. v. Signature Financial Group Inc.*, 47 USPQ2d 1596, 1600 (Fed. Cir. 1998), citing the U.S. Supreme Court's decision in *Diamond vs. Chakrabarty*, 206 USPQ 193 (S.Ct. 1980)).

The Action states that the present sequence lacks utility because the specification "no connection between any disease/condition" and the claimed sequence (Action at page 5). However, this is not the standard required for utility under 35 U.S.C. § 101. In *In re Brana*, (34 USPQ2d 1436 (Fed. Cir. 1995), "*Brana*"), the Federal Circuit admonished the P.T.O. for confusing "the requirements under the law for obtaining a patent with the requirements for obtaining government approval to market a particular drug for human consumption". *Brana* at 1442. The Federal Circuit went on to state:

At issue in this case is an important question of the legal constraints on patent office examination practice and policy. The question is, with regard to pharmaceutical inventions, what must the applicant provide regarding the practical utility or usefulness of the invention for which patent protection is sought. This is not a new issue; it is one which we would have thought had been settled by case law years ago.

Brana at 1439, emphasis added. The choice of the phrase "utility or usefulness" in the foregoing quotation is highly pertinent. The Federal Circuit is evidently using "utility" to refer to rejections under 35 U.S.C. § 101, and is using "usefulness" to refer to rejections under 35 U.S.C. § 112, first paragraph. This is made evident in the continuing text in *Brana*, which explains the correlation between 35 U.S.C. §§ 101 and 112, first paragraph. The Federal Circuit concluded:

FDA approval, however, is not a prerequisite for finding a compound useful within the meaning of the patent laws. Usefulness in patent law, and in particular in the context of pharmaceutical inventions, necessarily includes the expectation of further research and development. The stage at which an invention in this field becomes useful is well before it is ready to be administered to humans. Were we to require Phase II testing in order to prove utility, the associated costs would prevent many companies from obtaining patent protection on promising new inventions, thereby eliminating an incentive to pursue, through research and development, potential cures in many crucial areas such as the treatment of cancer.

Brana at 1442-1443, citations omitted. The Action states that the claimed sequences lack utility because "further experimentation" (the Action at page 5) would be required in certain aspects of the invention. Even if, *arguendo*, further research might be required in certain aspects of the present invention, this does not preclude a finding that the invention has utility, as set forth by the Federal Circuit's holding in *Brana*, which clearly states, as highlighted in the quote above, that "pharmaceutical inventions, necessarily includes the expectation of further research and development" (*Brana* at 1442-1443, emphasis added). In assessing the question of whether undue experimentation would be required

in order to practice the claimed invention, the key term is “undue”, not “experimentation”. *In re Angstadt and Griffin*, 190 USPQ 214 (CCPA 1976). The need for some experimentation does not render the claimed invention unpatentable. Indeed, a considerable amount of experimentation may be permissible if such experimentation is routinely practiced in the art. *In re Angstadt and Griffin, supra*; *Amgen, Inc. v. Chugai Pharmaceutical Co., Ltd.*, 18 USPQ2d 1016 (Fed. Cir. 1991). As a matter of law, it is well settled that a patent need not disclose what is well known in the art. *In re Wands*, 8 USPQ 2d 1400 (Fed. Cir. 1988).

The Action further states that the claims lack utility because “(t)he specification does not disclose any working examples demonstrating that the instant invention was used to treat any disease” (the Action at page 5). However, this position as applied to the presently claimed sequences is wholly unsupported by mandatory legal precedent. First, as described above, treatment of disease is not the proper standard for utility under 35 U.S.C. § 101. Second, it has long been established that “there is no statutory requirement for the disclosure of a specific example”. *In re Gay*, 135 USPQ 311 (CCPA, 1962).

Finally, the requirements set forth in the Action for compliance with 35 U.S.C. § 101 do not comply with the requirements set forth by the Patent and Trademark Office (“the PTO”) itself for compliance with 35 U.S.C. § 101. While Applicants are well aware of the new Utility Guidelines set forth by the USPTO, Applicants respectfully point out that the current rules and regulations regarding the examination of patent applications is and always has been the patent laws as set forth in 35 U.S.C. and the patent rules as set forth in 37 C.F.R., not the Manual of Patent Examination Procedure or particular guidelines for patent examination set forth by the USPTO. Furthermore, it is the job of the judiciary, not the USPTO, to interpret these laws and rules. Applicants are unaware of any significant recent changes in either 35 U.S.C. § 101, or in the interpretation of 35 U.S.C. § 101 by the Supreme Court or the Federal Circuit that is in keeping with the new Utility Guidelines set forth by the USPTO. This is underscored by numerous patents that have been issued over the years that claim nucleic acid fragments that do not comply with the new Utility Guidelines. As examples of such issued U.S. Patents, the Examiner is invited to review U.S. Patent Nos. 5,817,479, 5,654,173, and 5,552,281 (each of which claims short polynucleotides), and recently issued U.S. Patent No. 6,340,583 (which includes no working examples), none of which contain examples of the “real-world” utilities that the Examiner seems to be requiring. As issued U.S. Patents are presumed to meet all of the requirements for patentability, including 35 U.S.C. §§ 101 and 112, first paragraph (see Section IV, below), Applicants

submit that the present polynucleotides must also meet the requirements of 35 U.S.C. § 101. While Applicants understand that each application is examined on its own merits, Applicants are unaware of any changes to 35 U.S.C. § 101, or in the interpretation of 35 U.S.C. § 101 by the Supreme Court or the Federal Circuit, since the issuance of these patents that render the subject matter claimed in these patents, which is similar to the subject matter in question in the present application, as suddenly non-statutory or failing to meet the requirements of 35 U.S.C. § 101. Thus, holding Applicants to a different standard of utility would be arbitrary and capricious, and, like other clear violations of due process, cannot stand.

For each of the foregoing reasons, Applicants submit that as the presently claimed nucleic acid molecules have been shown to have a substantial, specific, credible and well-established utility, the rejection of claims 4-8 under 35 U.S.C. § 101 has been overcome, and request that the rejection be withdrawn.

IV. Rejection of Claims 4-8 Under 35 U.S.C. § 112, First Paragraph

The Action next rejects claims 4-8 under 35 U.S.C. § 112, first paragraph, since allegedly one skilled in the art would not know how to use the invention, as the invention allegedly is not supported by a specific, substantial, and credible utility or a well-established utility. Applicants respectfully traverse.

Applicants submit that as claims 4-8 have been shown to have “a specific, substantial, and credible utility”, as detailed in section III above, the present rejection of claims 4-8 under 35 U.S.C. § 112, first paragraph, cannot stand.

Applicants therefore request that the rejection of claims 4-8 under 35 U.S.C. § 112, first paragraph, be withdrawn.

V. Rejection of Claims 4, 7 and 8 Under 35 U.S.C. § 112, First Paragraph

The Action apparently next rejects claims 4, 7 and 8 under 35 U.S.C. § 112, first paragraph, as allegedly not providing enablement for “fragments of polynucleotides” (Action at page 6). While this rejection is not properly set forth in the Action, in that the specific claims being rejected are not identified, Applicants assume that this rejection is being applied only to claims 4, 7 and 8, because claims 5 and 6 do not read on “fragments of polynucleotides”. Nevertheless, with regard to the allegation that “the specification is not enabled for fragments of polynucleotides”, Applicants respectfully

traverse.

The Action states that "the specification is not enabled for fragments of polynucleotides" because "the changes which can be made in the structure and still maintain sufficient activity is unpredictable" (Action at page 6). Applicants point out that the above comment is completely irrelevant to determining whether the claimed compositions meet the legal requirements for patentability under 35 U.S.C. § 112, first paragraph. There is absolutely no requirement that all species of an invention must have all of the exact same properties. It is well established that the enablement requirement is met if any use of the invention (or in this case, certain species of the invention) is provided (*In re Nelson*, 126 USPQ 242 (CCPA 1960); *Cross v. Iizuka*, *supra*). "The enablement requirement is met if the description enables any mode of making and using the invention." *Johns Hopkins Univ. v. CellPro, Inc.*, 47 USPQ2d 1705, 1719 (Fed. Cir. 1998), citing *Engel Indus., Inc. v. Lockformer Co.*, 20 USPQ2d 1300, 1304 (Fed. Cir. 1991). The Examiner has already conceded that SEQ ID NO:6 is enabled. Thus, the enablement issue should be resolved. Enablement only requires that the specification describe a practical use for the composition defined in the claims, and that a skilled artisan be able to make and use the claimed DNA segments without undue experimentation. Accordingly, by the Examiner's own admission, the § 112 requirement has certainly been met.

The Action seems to contend that the specification provides insufficient guidance regarding the biological function or activity of certain of the claimed compositions. However, such an enablement standard conflicts with established patent law. As discussed *In re Brana*, *supra*, the Federal Circuit admonished the P.T.O. for confusing "the requirements under the law for obtaining a patent with the requirements for obtaining government approval to market a particular drug for human consumption". *Brana* at 1442.

The Examiner states that the present invention could not be practiced without "a large quantity of experimentation" (Action at page 6). However, it is important to remember that in assessing the question of whether undue experimentation would be required in order to practice the claimed invention, the key term is "undue", not "experimentation". *In re Angstadt and Griffin*, *supra*. In *In re Wands*, *supra*, the P.T.O. took the position that the applicant failed to demonstrate that the disclosed biological processes of immunization and antibody selection could reproducibly result in a useful biological product (antibodies from hybridomas) within the scope of the claims. In its decision overturning the P.T.O.'s rejection, the Federal Circuit found that Wands' demonstration of success in four out of nine cell lines screened was sufficient to support a conclusion of enablement. The court

emphasized that the need for some experimentation requiring, *e.g.*, production of the biological material followed by routine screening, was not a basis for a finding of non-enablement, stating:

Disclosure in application for the immunoassay method patent does not fail to meet enablement requirement of 35 USC 112 by requiring 'undue experimentation,' even though production of monoclonal antibodies necessary to practice invention first requires production and screening of numerous antibody producing cells or 'hybridomas,' since practitioners of art are prepared to screen negative hybridomas in order to find those that produce desired antibodies, since in monoclonal antibody art one 'experiment' is not simply screening of one hybridoma but rather is entire attempt to make desired antibody, and since record indicates that amount of effort needed to obtain desired antibodies is not excessive, in view of Applicants' success in each attempt to produce antibody that satisfied all claim limitations.

Wands at 1400. Thus, the need for some experimentation does not render the claimed invention unpatentable under 35 U.S.C. § 112, first paragraph. Indeed, a considerable amount of experimentation may be permissible if such experimentation is routinely practiced in the art. *In re Angstadt and Griffin, supra*; *Amgen, Inc. v. Chugai Pharmaceutical Co., Ltd., supra*.

Applicants point out that significant commercial exploitation of nucleic acid sequences requires no more information than the nucleic acid sequence itself. Applications ranging from gene expression analysis or profiling to chromosomal mapping are practiced utilizing nucleic acid sequences and techniques that are well-known to those of skill in the art. The widespread commercial exploitation of nucleic acid sequence information points to the level of skill in the art, and the enablement provided by disclosures such as the present specification, which include specific nucleic acid sequences and guidance regarding the various uses of such sequences.

The Action questions the teaching and guidance in the specification for certain aspects of the present invention. However, as discussed above, this requirement is completely misplaced. There is sufficient knowledge and technical skill in the art for a skilled artisan to be able to make and use the claimed DNA species in a number of different aspects of the invention entirely without further details in a patent specification. For example, it is not unreasonable to expect a Ph.D. level molecular biologist to be able to use the disclosed sequence to design oligonucleotide probes and primers and use them in, for example, PCR based screening and detection methods to obtain the described sequences and/or determine tissue expression patterns. Nevertheless, the present specification provides highly detailed descriptions of techniques that can be used to accomplish many different aspects of the claimed invention, including recombinant expression, site-specific mutagenesis, *in situ* hybridization, and large scale nucleic acid screening techniques, and properly incorporates by reference a montage of standard

texts into the specification, such as Sambrook *et al.* (*Molecular Cloning, A Laboratory Manual*) and Ausubel *et al.* (*Current Protocols in Molecular Biology*) to provide even further guidance to the skilled artisan. Incorporation of material into the specification by reference is proper. *Ex parte Schwarze*, 151 USPQ 426 (PTO Bd. App. 1966). The § 112, first paragraph rejection is thus *prima facie* improper:

As a matter of patent office practice, then, a specification disclosure which contains a teaching of the manner and process of making and using the invention in terms which correspond in scope to those used in describing and defining the subject matter sought to be patented must be taken as in compliance with the enabling requirement of the first paragraph of § 112 unless there is reason to doubt the objective truth of the statements contained therein which must be relied on for enabling support.

In re Marzocchi & Horton, 169 USPQ 367, 369 (CCPA 1971), emphasis as in original. In any event, an alleged lack of express teaching is insufficient to support a first paragraph rejection where one of skill in the art would know how to perform techniques required to perform at least one aspect of the invention. As a matter of law, it is well settled that a patent need not disclose what is well known in the art. *In re Wands, supra*. In fact, it is preferable that what is well known in the art be omitted from the disclosure. *Hybritech, Inc. v. Monoclonal Antibodies, Inc.*, 231 USPQ 81 (Fed. Cir. 1986). As standard molecular biological techniques are routine in the art, such protocols do not need to be described in detail in the specification.

Furthermore, a specification "need describe the invention only in such detail as to enable a person skilled in the most relevant art to make and use it." *In re Naquin*, 158 USPQ 317, 319 (CCPA 1968); emphasis added. The present claims are thus enabled as they are supported by a specification that provides sufficient description to enable the skilled person to make and use the invention as claimed.

As detailed above, and in the previous response, all aspects of the enablement rejection under 35 U.S.C. § 112, first paragraph have been overcome. Applicants therefore respectfully request that the rejection be withdrawn.

VI. Rejection of Claims 4 and 5 Under 35 U.S.C. § 112, First Paragraph

The Action next rejects claims 4 and 5 under 35 U.S.C. § 112, first paragraph, as allegedly containing subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. Applicants respectfully traverse.

35 U.S.C. § 112, first paragraph, requires that the specification contain a written description of the invention. The Federal Circuit in *Vas-Cath Inc. v. Mahurkar* (19 USPQ2d 1111 (Fed. Cir. 1991); “*Vas-Cath*”) held that an “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of *the invention*.” *Vas-Cath*, at 1117, emphasis in original. However, it is important to note that the above finding uses the terms reasonable clarity to those skilled in the art. Further, the Federal Circuit in *In re Gosteli* (10 USPQ2d 1614 (Fed. Cir. 1989); “*Gosteli*”) held:

Although [the applicant] does not have to describe exactly the subject matter claimed, . . . the description must clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.

Gosteli at 1618, emphasis added. Additionally, *Utter v. Hiraga* (6 USPQ2d 1709 (Fed. Cir. 1988); “*Utter*”), held “(a) specification may, within the meaning of 35 U.S.C. § 112 ¶1, contain a written description of a broadly claimed invention without describing all species that claim encompasses” (*Utter*, at 1714). Therefore, all Applicants must do to comply with 35 U.S.C. § 112, first paragraph, is to convey the invention with reasonable clarity to the skilled artisan.

Further, the Federal Circuit has held that an adequate description of a chemical genus “requires a precise definition, such as by structure, formula, chemical name or physical properties” sufficient to distinguish the genus from other materials. *Fiers v. Sugano*, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993; “*Fiers*”). *Fiers* goes on to hold that the “application satisfies the written description requirement since it sets forth the . . . nucleotide sequence” (*Fiers* at 1607). In other words, provision of a structure and formula - the nucleotide sequence - renders the application in compliance with 35 U.S.C. § 112, first paragraph.

More recently, the standard for complying with the written description requirement in claims involving chemical materials has been explicitly set forth by the Federal Circuit:

In claims involving chemical materials, generic formulae usually indicate with specificity what the generic claims encompass. One skilled in the art can distinguish such a formula from others and can identify many of the species that the claims encompass. Accordingly, such a formula is normally an adequate description of the claimed genus. *Univ. of California v. Eli Lilly and Co.*, 43 USPQ2d 1398, 1406 (Fed. Cir. 1997).

Thus, a claim describing a genus of nucleic acids by structure, formula, chemical name or physical properties sufficient to allow one of ordinary skill in the art to distinguish the genus from other materials meets the written description requirement of 35 U.S.C. § 112, first paragraph. As further elaborated by the Federal Circuit in *Univ. of California v. Eli Lilly and Co.*:

In claims to genetic material ... a generic statement such as 'vertebrate insulin cDNA' or 'mammalian insulin cDNA', without more, is not an adequate written description of the genus because it does not distinguish the claimed genus from others, except by function. It does not specifically define any of the genes that fall within its definition. It does not define any structural features commonly possessed by members of the genus that distinguish them from others. One skilled in the art cannot, as one can do with a fully described genus, visualize or recognize the identity of members of the genus. (Emphasis added)

Thus, as opposed to the situation set forth in *Univ. of California v. Eli Lilly and Co.* and *Fiers*, the nucleic acid sequences of the present invention are not distinguished on the basis of function, or a method of isolation, but in fact are distinguished by structural features - a chemical formula, *i.e.*, the *sequence itself*.

Using the nucleic acid and amino acid sequences of the present invention (as set forth in the Sequence Listing), the skilled artisan would readily be able to distinguish the claimed nucleic acids from other materials on the basis of the specific structural description provided. Polynucleotides comprising at least 24 contiguous nucleotides from the nucleotide sequence of SEQ ID NO:6, or a nucleotide sequence that encodes SEQ ID NO:7 and hybridizes to SEQ ID NO:6 or the complement thereof under specific highly stringent hybridization conditions, are within the genus of the instant claims, while those that lack this structural feature lie outside the genus. Claims 4 and 5 thus meet the written description requirement.

For each of the foregoing reasons, Applicants submit that the rejection of claims 4 and 5 under 35 U.S.C. § 112, first paragraph, has been overcome, and request that the rejection be withdrawn.

VII. Rejection of Claim 5 Under 35 U.S.C. § 112, Second Paragraph

The Action next rejects claim 5 under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the invention.

The Action rejects claim 5 as allegedly indefinite based on the term "highly stringent hybridization conditions", because the specific hybridization and washing conditions are not recited in the claim. Applicants stress that "a claim need not 'describe' the invention, such description being the role of the disclosure". *Orthokinetics, Inc. v. Safety Travel Chairs, Inc.*, 1 USPQ2d 1081, 1088 (Fed. Cir. 1986). However, while Applicants submit that the term is sufficiently definite, as a number of stringent hybridization conditions are defined in the specification and would be known to those of skill in the art, solely in order to progress the case more rapidly toward allowance the claim has been revised

to recite specific highly stringent hybridization conditions. As the specification provides specific teaching regarding such highly stringent hybridization conditions, at least at page 8, lines 5-14, Applicants submit that revised claim 5 even more clearly meets the requirements of 35 U.S.C. § 112, second paragraph. Applicants therefore request withdrawal of this rejection.

VIII. Conclusion

The present document is a full and complete response to the Action. In conclusion, Applicants submit that, in light of the foregoing remarks, the present case is in condition for allowance, and such favorable action is respectfully requested. Should Examiner DeBerry have any questions or comments, or believe that certain amendments of the claims might serve to improve their clarity, a telephone call to the undersigned Applicants' representative is earnestly solicited.

Respectfully submitted,

March 6, 2003

Date



David W. Hibler
Agent for Applicants

Reg. No. 41,071

LEXICON GENETICS INCORPORATED
8800 Technology Forest Place
The Woodlands, TX 77381
(281) 863-3399



24231

PATENT TRADEMARK OFFICE